XML 55 R39.htm IDEA: XBRL DOCUMENT

Segment Reporting (Tables)

12 Months Ended

Dec. 31, 2025

Segment Reporting

Schedule of activity of Company's segments


		For the Years Ended December 31,
		2025												2024
		Ophthalmic			Digital			Corporate/						Ophthalmic			Digital			Corporate/
		Technology			Assets			Other			Total			Technology			Assets			Other			Total
Revenue:
Revenue		$	14,720		$	798,735		$	—		$	813,455		$	57,336		$	—		$	—		$	57,336
Less:
Cost of revenue			(48)			(303,242)			—			(303,290)			(3,927,228)			—			—			(3,927,228)
Gross Income (Loss)			14,672			495,493			—			510,165			(3,869,892)			—			—			(3,869,892)
Less:
Research and Development:
Salaries and benefits			1,099,840			—			—			1,099,840			6,215,323			—			—			6,215,323
Direct clinical and non-clinical expenses			151,180			—			—			151,180			3,072,416			—			—			3,072,416
Facilities expenses			190,182			—			—			190,182			834,406			—			—			834,406
Non-cash stock based compensation expenses			389,245			—			—			389,245			623,049			—			—			623,049
Supplies and materials			25,130			—			—			25,130			2,195,608			—			—			2,195,608
Other Expenses⁽¹⁾			42,165			—			—			42,165			409,457			—			—			409,457
Depreciation expense			12,688			—			—			12,688			1,112,463			—			—			1,112,463
Realized gain - digital assets			—			(8,321,844)			—			(8,321,844)			—			—			—			—
Unrealized gain/loss - digital assets			—			9,030,413			—			9,030,413			—			—			—			—
Impairment loss - digital assets			—			27,188,768			—			27,188,768			—			—			—			—
Impairment loss - other assets			—			—			—			—			11,207,897			—			—			11,207,897
Gain on covered call option			—			(157,570)			—			(157,570)			—			—			—			—
Provision for credit losses			—			405,331			—			405,331			—			—			—			—
Reacquisition of license rights			—			—			—			—			4,864,600			—			—			4,864,600
Segment loss			1,910,430			28,145,098			—			30,055,528			30,535,219			—			—			30,535,219

Reconciling Items
Selling, general and administrative expense ⁽²⁾			—			—			17,175,698			17,175,698			14,333,114			—			—			14,333,114
Other (income) expense, net ⁽³⁾			—			—			(1,406,626)			(1,406,626)			(1,080,208)			—			—			(1,080,208)

Net Income (Loss)		$	(1,895,758)		$	(27,649,605)		$	(15,769,072)		$	(45,314,435)		$	(49,818,433)		$	—		$	—		$	(49,818,433)

(1)	Other research and development expenses include outsourced engineering and IT systems used for research and development.

(2)	Selling, general and administrative expenses primarily include professional fees, general and administrative compensation expenses, general strategic consulting, Nasdaq/SEC fees, insurance and facilities expenses.

(3)	Other (income) expense, net includes interest income, interest expense and gain on extinguishment of liabilities.

Schedule of segment assets


		December 31, 2025												December 31, 2024
		Ophthalmic			Digital			Corporate/						Ophthalmic			Digital			Corporate/
		Technology			Assets			Other			Total			Technology			Assets			Other			Total
Segment Assets
Cash		$	—		$	—		$	6,443,467		$	6,443,467		$	2,121,463		$	—		$	—		$	2,121,463
Digital assets			—			43,872,033			—			43,872,033			—			—			—			—
All other assets			132,652			—			1,316,104			1,448,756			1,546,296			—			—			1,546,296
Total Assets		$	132,652		$	43,872,033		$	7,759,571		$	51,764,256		$	3,667,759		$	—		$	—		$	3,667,759